Eagle Pharmaceuticals Valuation

Eagle Pharmaceuticals Investor Information

About 12.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.1. Some equities with similar Price to Book (P/B) outperform the market in the long run. Eagle Pharmaceuticals has Price/Earnings To Growth (PEG) ratio of 0.91. The entity had not issued any dividends in recent years. Based on the key indicators related to Eagle Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Eagle Pharmaceuticals is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April.

Eagle Pharmaceuticals Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Eagle Pharmaceuticals has an asset utilization ratio of 77.95 percent. This suggests that the Company is making $0.78 for each dollar of assets. An increasing asset utilization means that Eagle Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.

Eagle Pharmaceuticals Ownership Allocation

The market capitalization of Eagle Pharmaceuticals is $27.73 Million. The majority of Eagle Pharmaceuticals outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Eagle Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Eagle Pharmaceuticals. Please pay attention to any change in the institutional holdings of Eagle Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.

Eagle Pharmaceuticals Profitability Analysis

The company reported the previous year's revenue of 316.61 M. Net Loss for the year was (2.67 M) with profit before overhead, payroll, taxes, and interest of 221.67 M.

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.

Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

If you are still planning to invest in Eagle Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eagle Pharmaceuticals' history and understand the potential risks before investing.